Close
Smartlab Europe
Inizio Ignite

Majority UK oncologists prefer Doctors.net.uk

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...

J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant

Johnson & Johnson announced that it plans to invest...

Precision Cellular Analysis Powering the Next Generation

Biopharmaceutical innovation increasingly depends on understanding biology at the...
- Advertisement -
Smart Lab Europe

Almost 51% of the Oncologists in the UK are said to be using online cancer research center, Doctors.net.uk.The center offers all news, information and research on the five most common cancers in the UK.It also provides access to advice from specialist oncology advisers and a secure online forum where doctors can share information. Doctors.net.uk medical director Tim Ringrose said the Cancer Insight Centre fulfils a clear need for up to the minute educational resources that enable oncologists and other medical professionals to learn and collaborate with each other in a secure, professional online environment.

“The resources have already proved so popular among medical professionals, particularly oncologists, and we believe that they will continue provide an invaluable source of information and support,” Ringrose said.

Smart Lab Europe

Latest stories

Related stories

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Eli Lilly said that its weight-loss medicine Zepbound, when...

J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant

Johnson & Johnson announced that it plans to invest...

Precision Cellular Analysis Powering the Next Generation

Biopharmaceutical innovation increasingly depends on understanding biology at the...

FDA Approves Monthly Rybrevant Faspro for EGFR-Mutated NSCLC

Johnson & Johnson (J&J) has obtained approval from the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »